THCC-RI在HCC早期检测策略研究中的外部验证
本研究在美国7中心前瞻性肝硬化队列(HEDS研究,1560例,5051人年)中外部验证THCC-RI。中位随访2.5年,114例发生HCC;THCC-RI的C-index为0.77,1、3、5年AUC分别为0.77、0.73、0.71,校准良好;高危组(9-10分位)HCC风险是中危组(3-8分位)的3.5倍(HR=3.5,95%CI 2.4-5.1)。
要点
- THCC-RI在独立多中心肝硬化队列中表现出良好的HCC风险预测效能,C-index为0.77。
- THCC-RI高危组(9-10分位)HCC风险是 medium 危组(3-8分位)的3.5倍(HR=3.5,95%CI 2.4-5.1)。
- THCC-RI在5年随访内判别力和校准稳定,3年后AUC下降幅度小于aMAP评分。
核心结论
- THCC-RI在独立多中心肝硬化队列中预测HCC风险表现良好,5年随访内判别力与校准稳定,但融入临床路径仍需进一步研究。
研究设计与样本
- 前瞻性队列外部验证研究,使用HCC早期检测策略(HEDS)研究数据,纳入美国7中心接受规律HCC监测的肝硬化患者1560例,共5051人年随访。
主要发现
- 中位随访2.5年,114例患者发生HCC。
- THCC-RI的C-index为0.77(95%CI 0.64-0.85),1年AUC为0.77(95%CI 0.65-0.85),3年AUC为0.73(95%CI 0.66-0.79),5年AUC为0.71(95%CI 0.65-0.77)。
- THCC-RI校准良好,观察风险与预测风险一致性佳。
- 高危组(9、10分位)HCC风险是 medium 危组(3-8分位)的3.5倍(HR=3.5,95%CI 2.4-5.1)。
- THCC-RI在随访前2年判别力与aMAP评分相似,但超过3年后aMAP的AUC下降幅度大于THCC-RI。
临床怎么用
- THCC-RI可用于肝硬化患者HCC风险分层,高危组(9-10分位)风险显著升高,或可辅助制定监测策略;但融入临床路径仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We previously developed a hepatocellular carcinoma (HCC) risk stratification model, the Texas HCC Consortium Risk Index (THCC-RI), for patients with cirrhosis. In this cohort study, we aimed to externally validate THCC-RI in a prospective cohort of patients with cirrhosis. METHODS: We used data from the Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study, a prospective cohort of patients with cirrhosis enrolled in regular HCC surveillance at 7 centers in the United States. Patients were followed from enrollment until HCC diagnosis, liver transplantation, death, or December 2023. RESULTS: The analysis was conducted in 1560 patients who contributed a total of 5051 person-years of follow-up (mean age, 59 years; 47% women; 40% with hepatitis C; 16% alcohol-associated disease; and 22% metabolic dysfunction-associated steatotic liver disease). Over a median follow-up of 2.5 years, 114 patients developed HCC. The THCC-RI had a C-index of 0.77 (95% confidence interval [CI], 0.64-0.85), with area under the receiver operating characteristic curve estimates of 0.77 (95% CI, 0.65-0.85) at 1 year, 0.73 (95% CI, 0.66-0.79) at 3 years, and 0.71 (95% CI, 0.65-0.77) at 5 years. THCC-RI was well-calibrated, with good agreement between observed and predicted risk. Compared with the medium-risk group (deciles 3-8), the high-risk group (deciles 9, 10) had 3.5-fold (hazard ratio, 3.5; 95% CI, 2.4-5.1) higher risk of HCC. THCC-RI had similar discrimination as the Age, Male, Albumin-bilirubin, and Platelets (aMAP) score during the first 2 years of follow-up, but the areas under the receiver operating characteristic curve for aMAP dropped more than those for THCC-RI as the time horizon expanded beyond 3 years. CONCLUSIONS: In an independent multi-center cohort, THCC-RI had good performance for predicting the future risk of HCC in patients with cirrhosis, with stable discrimination and calibration over a 5-year follow-up. Implementation of THCC-RI into clinical care pathways requires further research.
引用
- Kanwal F, Lopez C, Ning J, et al. Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study. Clin Gastroenterol Hepatol. 2026. PMID: 41672261. doi:10.1016/j.cgh.2026.01.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。